{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:01:21Z","timestamp":1771002081426,"version":"3.50.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1097\/mjt.0b013e31818bee2b","type":"journal-article","created":{"date-parts":[[2009,11,14]],"date-time":"2009-11-14T08:18:26Z","timestamp":1258186706000},"page":"585-590","source":"Crossref","is-referenced-by-count":14,"title":["Lapatinib Plus Capecitabine Resolved Human Epidermal Growth Factor Receptor 2-Positive Brain Metastases"],"prefix":"10.1097","volume":"16","author":[{"given":"Stefan","family":"Gl\u00fcck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelio","family":"Castrellon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-22-20210202","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene.","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"R3-22-20210202","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer.","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"R4-22-20210202","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"R5-22-20210202","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1002\/cncr.11436","article-title":"Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.","volume":"97","author":"Bendell","year":"2003","journal-title":"Cancer"},{"key":"R6-22-20210202","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.breast.2005.04.017","article-title":"Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.","volume":"15","author":"Stemmler","year":"2006","journal-title":"Breast"},{"key":"R7-22-20210202","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1200\/JCO.2000.18.11.2349","article-title":"Trastuzumab in CSF.","volume":"18","author":"Pestalozzi","year":"2000","journal-title":"J Clin Oncol"},{"key":"R8-22-20210202","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/01.pas.0000213306.05811.b9","article-title":"Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5\/6, and overexpress HER2 or EGFR.","volume":"30","author":"Hicks","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"R9-22-20210202","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/annonc\/mdg300","article-title":"Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival.","volume":"14","author":"Miller","year":"2003","journal-title":"Ann Oncol"},{"key":"R10-22-20210202","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/annonc\/mdh432","article-title":"Risk factors for brain relapse in patients with metastatic breast cancer.","volume":"15","author":"Slimane","year":"2004","journal-title":"Ann Oncol"},{"key":"R11-22-20210202","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol"},{"key":"R12-22-20210202","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0360-3016(02)02967-X","article-title":"Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study.","volume":"54","author":"Mahmoud-Ahmed","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R14-22-20210202","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10549-007-9885-0","article-title":"A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.","volume":"112","author":"Cameron","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"R15-22-20210202","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer.","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"R16-22-20210202","first-page":"35s","article-title":"EGF105084, a phase II study of lapatinib for brain metastases in patients with HER2+ breast cancer following trastuzumab based systemic therapy and cranial radiotherapy [ASCO abstract 1012].","volume":"25","author":"Lin","year":"2007","journal-title":"J Clin Oncol"},{"key":"R18-22-20210202","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3816\/CBC.2006.n.028","article-title":"Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report.","volume":"7","author":"Tham","year":"2006","journal-title":"Clin Breast Cancer"},{"key":"R19-22-20210202","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11060-007-9409-0","article-title":"Capecitabine therapy of central nervous system metastases from breast cancer.","volume":"85","author":"Ekenel","year":"2007","journal-title":"J Neurooncol"},{"key":"R20-22-20210202","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/cncr.22127","article-title":"Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.","volume":"107","author":"Rivera","year":"2006","journal-title":"Cancer"},{"key":"R21-22-20210202","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.breast.2005.03.006","article-title":"Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse.","volume":"15","author":"Hikino","year":"2006","journal-title":"Breast"},{"key":"R22-22-20210202","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.2007.11.9776","article-title":"Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.","volume":"25","author":"Bartsch","year":"2007","journal-title":"J Clin Oncol"},{"key":"R23-22-20210202","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/annonc\/mdl064","article-title":"Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).","volume":"17","author":"Pestalozzi","year":"2006","journal-title":"Ann Oncol"},{"key":"R24-22-20210202","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","article-title":"Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.","volume":"18","author":"Stemmler","year":"2007","journal-title":"Anticancer Drugs"},{"key":"R25-22-20210202","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1158\/1078-0432.CCR-06-2478","article-title":"Brain metastases: the HER2 paradigm.","volume":"13","author":"Lin","year":"2007","journal-title":"Clin Cancer Res"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00045391-200911000-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:40:30Z","timestamp":1618036830000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-200911000-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e31818bee2b","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}